Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -70.00K | -6.35M | -5.71M | -3.42M | -2.84M | -2.35M |
EBITDA | -68.60M | -64.43M | -74.30M | -60.20M | -47.66M | -13.40M |
Net Income | -65.69M | -70.78M | -63.67M | -57.92M | -50.31M | -15.62M |
Balance Sheet | ||||||
Total Assets | 213.19M | 242.74M | 305.56M | 350.05M | 398.45M | 85.01M |
Cash, Cash Equivalents and Short-Term Investments | 147.87M | 129.89M | 173.42M | 184.47M | 345.73M | 76.74M |
Total Debt | 28.18M | 30.48M | 34.63M | 30.33M | 30.03M | 4.78M |
Total Liabilities | 32.09M | 34.01M | 40.21M | 35.13M | 34.87M | 114.73M |
Stockholders Equity | 181.09M | 208.73M | 265.35M | 314.92M | 363.58M | -29.72M |
Cash Flow | ||||||
Free Cash Flow | -56.29M | -61.27M | -54.15M | -48.13M | -41.51M | -14.92M |
Operating Cash Flow | -54.71M | -59.15M | -51.71M | -45.81M | -39.24M | -14.00M |
Investing Cash Flow | 63.59M | 66.25M | -43.73M | -25.74M | -138.96M | -25.28M |
Financing Cash Flow | 693.00K | 1.14M | 368.00K | 562.00K | 327.45M | 75.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
49 Neutral | $113.24M | ― | -25.25% | ― | 12.13% | -8.23% | |
47 Neutral | $148.38M | ― | -313.82% | ― | 41.61% | -17.39% | |
41 Neutral | $82.33M | ― | -31.55% | ― | ― | 6.27% | |
― | $90.85M | ― | -15.23% | ― | ― | ― | |
34 Underperform | $204.68M | ― | -51.74% | ― | ― | 29.72% | |
33 Underperform | $263.97M | ― | -89.37% | ― | ― | 9.84% |
Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.